Want to see ALGS full AI Analyst Report?
ALGS Stock Chart & Stats
$4.08
-$0.61(-13.01%)
At close: 4:00 PM EDT
$4.08
-$0.61(-13.01%)
Day’s Range― - ―
52-Week Range$3.98 - $13.69
Previous CloseN/A
Volume203.10K
Average Volume (3M)223.79K
Market Cap
$43.03M
Enterprise Value$33.27
Total Cash (Recent Filing)$30.38M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.30
Shares Outstanding5,444,558
10 Day Avg. Volume101,329
30 Day Avg. Volume223,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.50Price Target Upside1676.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.55
Revenue Forecast (FY)$35.99M
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe high reported gross margin indicates favorable economics on current revenue and provides a potentially strong foundation if Aligos can advance candidates, expand revenue, and bring operating costs closer to its commercial scale.
Modest LeverageLow debt reduces refinancing and solvency pressure relative to more leveraged biotech companies. This preserves financial flexibility, although the benefit is limited by ongoing losses and the company’s dependence on external capital.
Focused Therapeutic PipelineA focused small-molecule strategy in chronic HBV and NASH gives Aligos a defined therapeutic direction and the potential to build specialized expertise, though value creation remains dependent on clinical execution and approvals.
Bears Say
Persistent Cash BurnSubstantial recurring cash consumption means the business is not self-funding. Continued research and clinical spending may require additional financing, increasing dilution risk and limiting flexibility if capital markets become less supportive.
Sustained Operating LossesPersistent losses show that current revenue is far below the expense base required to run the company and fund development. Without successful clinical or commercial progress, profitability remains difficult to achieve over the medium term.
Declining Revenue And Balance-Sheet FragilityShrinking revenue weakens internal funding capacity, while previously negative equity highlights sensitivity to accumulated losses. Together, these factors increase the likelihood of future capital needs and potential shareholder dilution.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics, Inc.’s price range in the past 12 months?
Aligos Therapeutics, Inc. lowest stock price was $3.98 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics, Inc.’s market cap?
Aligos Therapeutics, Inc.’s market cap is $43.03M.
When is Aligos Therapeutics, Inc.’s upcoming earnings report date?
Aligos Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2027 which is in 202 days.
How were Aligos Therapeutics, Inc.’s earnings last quarter?
Aligos Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$1.094 by $0.954.
Is Aligos Therapeutics, Inc. overvalued?
According to Wall Street analysts Aligos Therapeutics, Inc.’s price is currently Undervalued.
Does Aligos Therapeutics, Inc. pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
What is Aligos Therapeutics, Inc.’s EPS estimate?
Aligos Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has 5,444,558 shares outstanding.
What happened to Aligos Therapeutics, Inc.’s price movement after its last earnings report?
Aligos Therapeutics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$1.094. Following the earnings report the stock price went up 16.245%.
Which hedge fund is a major shareholder of Aligos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.50 (1676.96% Upside)
$72.50 (1676.96% Upside)
Blogger Sentiment
Bullish
ALGS Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 111.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.76%
Trailing 12-Months
Company Description
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$72.50
▲(1676.96% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
46.67%
Insiders
4.22% Mutual Funds
31.17% Other Institutional Investors
14.58% Public Companies and
Individual Investors